Perillyl Alcohol (Monoterpene Alcohol), Limonene

Shojaei, Shahla; Kiumarsi, Amir; Moghadam, Adel Rezaei; Alizadeh, Javad; Marzban, Hassan; Ghavami, Saeid

doi:10.1016/b978-0-12-802215-3.00002-1

Cited by 31 publications

(27 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many fruits and vegetables contail Limonene (monoterpene), it consist of two isoprene units, having >90% essential oil. However, nearly two decades ago, the anticancer potential of D-limonene was estimated, but very recently many researchers are attracted towards it to develop medicines for the treatment of cancer 4 . Qualitative and quantitative evaluation of chemical constituents was done by the means of GC-MS. Total 54 components were detected in essential oil and 44 components were detected in the extracts.…”

Section: Resultsmentioning

confidence: 99%

Phytochemical Profile With Anti-Tumor Activity Estimation of Crude Extract, Essential Oil and D-Limonene From Citrus Aurantium L. Against Ehrlich Carcinoma

Gregório

et al. 2020

Univ J Pharm Res

View full text Add to dashboard Cite

Objective: Plant based drugs have been a solution in the search for more cost-effective and less harmful drugs for the treatment of neoplasia. Citrus aurantium L. (Rutaceae) is abundant in Brazil and D-limonene, a monoterpene used in the prevention and treatment of neoplasia, was identified as a major compound in the oil of this specie. Objective of current study includes estimation of anti-tumor activity of Citrus aurantium L. (Rutaceae) (crude extract, essential oil and D-limonene) against Ehrlich carcinoma, as well as their phytochemical evaluation (D-limonene and essential oil). Methods: There was a randomized non-clinical trial in which were used adult male mice (Balb-C). Four groups of animals were used having 6 numbers of animal in each group. All groups were inoculated with the Ehrlich tumor and then received the treatment (control, crude extract, essential oil and D-limonene) by oral route daily (28 day treatment). Essential oil was obtained by hydro-distillation and analyzed by the means of GC (Gas Chromatography) that was attached to mass spectrometry. In last of the observations hemogram was obtained. Results: Animals treated with the essential oil has shown no significant difference compared to the group treated with D-limonene. The group treated with crude extract had a growth inhibition close to the essential oil and D-limonene groups. Conclusion: It´s concluded that the essential oil and the crude extract of Citrus aurantium, L. (Rutaceae) can become therapeutic agents because of their anti-tumor activity with no toxicity to the blood cells and have low cost of production. Further studies are necessary, so they can be used in the treatment of neoplasia in humans. The chromatographic and spectrometric analyzes indicated the presence of other components in smaller amounts in the essential oil, which suggests that they could have a synergic activity to the D-limonene. Peer Review History: Received 2 June 2020; Revised 25 June; Accepted 4 July, Available online 15 July 2020 UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file Average Peer review marks at initial stage: 6.0/10 Average Peer review marks at publication stage: 8.0/10 Reviewer(s) detail: Name: Ahmad Najib Affiliation: Universitas Muslim Indonesia, Makassar, Indonesia E-mail: ahmad.najib@umi.ac.id Name: Dr. Mohamed Said Fathy Al-Refaey Affiliation: University of Sadat City, Menofia, Egypt E-mail: mido_ph212@yahoo.com Comments of reviewer(s): Similar Articles: CYTOTOXIC EFFECT AND PHYTOCHEMICAL STUDY OF PETROLEUM ETHER EXTRACT OF TILIA CORDATA MILL

show abstract

Section: Resultsmentioning

confidence: 99%

Phytochemical Profile With Anti-Tumor Activity Estimation of Crude Extract, Essential Oil and D-Limonene From Citrus Aurantium L. Against Ehrlich Carcinoma

Gregório

et al. 2020

Univ J Pharm Res

View full text Add to dashboard Cite

show abstract

“…All these effects were mediated by downregulation of phosphorylation of VEGFR2 and fibroblast growth factor receptor-1, two essential signaling pathways for angiogenesis [ 195 , 196 ]. Perillyl alcohol, a component of Anethum graveolens, Conyza newii and Citrus limon EOs [ 197 ], blocked the growth of new blood vessel in the in vivo CAM assay and inhibited the in vitro morphogenic differentiation of endothelial cells. Perillyl alcohol also reduced proliferation and induced both apoptosis and the expression of the antiangiogenic molecule, angiopoietin 2, in endothelial cells, indicating that it exerted its effect through both vessel regression and neovascularization suppression [ 198 ].…”

Section: Mechanism Of Action Of Eos In Melanomamentioning

confidence: 99%

Essential Oils and Their Main Chemical Components: The Past 20 Years of Preclinical Studies in Melanoma

Martile

Garzoli

Ragno

et al. 2020

Cancers

View full text Add to dashboard Cite

The last two decades have seen the development of effective therapies, which have saved the lives of a large number of melanoma patients. However, therapeutic options are still limited for patients without BRAF mutations or in relapse from current treatments, and severe side effects often occur during therapy. Thus, additional insights to improve treatment efficacy with the aim to decrease the likelihood of chemoresistance, as well as reducing side effects of current therapies, are required. Natural products offer great opportunities for the discovery of antineoplastic drugs, and still represent a useful source of novel molecules. Among them, essential oils, representing the volatile fraction of aromatic plants, are always being actively investigated by several research groups and show promising biological activities for their use as complementary or alternative medicine for several diseases, including cancer. In this review, we focused on studies reporting the mechanism through which essential oils exert antitumor action in preclinical wild type or mutant BRAF melanoma models. We also discussed the latest use of essential oils in improving cancer patients’ quality of life. As evidenced by the many studies listed in this review, through their effect on apoptosis and tumor progression-associated properties, essential oils can therefore be considered as potential natural pharmaceutical resources for cancer management.

show abstract

“…At present, the majority of studies indicate that this model is not generally applicable, but that it may potentially be isoform-specific and dependent on distinct cell growth conditions. In comparison, inhibition of overall Ras protein synthesis, and related small-molecule GTPases [87,99,107,108], by POH appears well documented, although this level of regulation seems independent of the monoterpene’s impact on the mevalonate pathway. Rather, it adds Ras to the general list of protein targets that are presented in Section 4.1 above.…”

Section: Perillyl Alcoholmentioning

confidence: 99%

Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development

Chen

Fonseca

Schönthal

2018

IJMS

View full text Add to dashboard Cite

Intracranial malignancies, such as primary brain cancers and brain-localized metastases derived from peripheral cancers, are particularly difficult to treat with therapeutic agents, because the blood-brain barrier (BBB) effectively minimizes brain entry of the vast majority of agents arriving from the systemic circulation. Intranasal administration of cancer drugs has the potential to reach the brain via direct nose-to-brain transport, thereby circumventing the obstacle posed by the BBB. However, in the field of cancer therapy, there is a paucity of studies reporting positive results with this type of approach. A remarkable exception is the natural compound perillyl alcohol (POH). Its potent anticancer activity was convincingly established in preclinical studies, but it nonetheless failed in subsequent clinical trials, where it was given orally and displayed hard-to-tolerate gastrointestinal side effects. Intriguingly, when switched to intranasal delivery, POH yielded highly promising activity in recurrent glioma patients and was well tolerated. As of 2018, POH is the only intranasally delivered compound in the field of cancer therapy (outside of cancer pain) that has advanced to active clinical trials. In the following, we will introduce this compound, summarize its molecular mechanisms of action, and present the latest data on its clinical evaluation as an intranasally administered agent for glioma.

show abstract

Perillyl Alcohol (Monoterpene Alcohol), Limonene

Cited by 31 publications

References 79 publications

Phytochemical Profile With Anti-Tumor Activity Estimation of Crude Extract, Essential Oil and D-Limonene From Citrus Aurantium L. Against Ehrlich Carcinoma

Phytochemical Profile With Anti-Tumor Activity Estimation of Crude Extract, Essential Oil and D-Limonene From Citrus Aurantium L. Against Ehrlich Carcinoma

Essential Oils and Their Main Chemical Components: The Past 20 Years of Preclinical Studies in Melanoma

Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development

Contact Info

Product

Resources

About